GlassScriptPhysician profile
Mohsen Nasir
NPI 1528287240
$98,619.16
in general payments reported to CMS, 2019-2025
29 companies · $3,505 in 2025
The $3,505 reported for 2025 was more than what 79% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,515 · 2021: $127 · 2022: $242 · 2023: $91K · 2024: $851 · 2025: $3,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $90K · Consulting Fee: $3,189 · Food and Beverage: $2,964 · Education: $51.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $89,530.19 |
| Consulting Fee | $3,189.00 |
| Food and Beverage | $2,963.93 |
| Education | $51.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $89,530.19 | 2023 | |
| Genzyme Corporation | $3,496.49 | 2021-2025 | |
| Shire North American Group INC | $2,490.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $470.71 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $371.03 | 2021-2025 | Hyqvia, Cuvitru, Eohilia |
| Glaxosmithkline, LLC. | $354.84 | 2021-2025 | Nucala |
| Csl Behring | $327.75 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Alnylam Pharmaceuticals INC. | $250.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $234.82 | 2022-2025 | |
| Octapharma USA, INC. | $204.17 | 2023-2025 | Cutaquig, Panzyga |
| Regeneron Healthcare Solutions, INC. | $180.25 | 2022-2025 | Dupixent |
| Amgen INC. | $147.66 | 2023-2025 | Tezspire |
| Genentech USA, INC. | $134.10 | 2022-2025 | Xolair, Ocrevus Zunovo |
| Sk Life Science, INC. | $59.68 | 2023-2025 | |
| Pfizer INC. | $56.60 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $49.30 | 2025 | Vtama |
| Ars Pharmaceuticals Operations, INC. | $46.53 | 2025 | Neffy |
| Dermavant Sciences, INC. | $23.51 | 2024 | Vtama |
| Abbvie INC. | $22.19 | 2024 | |
| Azurity Pharmaceuticals, INC. | $20.59 | 2024 | Horizant |
| Hospira, INC. | $19.19 | 2025 | |
| Inspire Medical Systems, INC. | $18.72 | 2025 | Inspire |
| Kerecis Limited | $18.59 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Neurelis, INC. | $16.77 | 2025 | Valtoco |
| Galderma Laboratories, L.P. | $16.14 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $15.50 | 2025 | Ayvakit |
| Genentech, INC. | $15.03 | 2023 | Xolair |
| Hikma Pharmaceuticals USA | $14.68 | 2024 | Ryaltris |
| Phadia US INC. | $14.13 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsen Nasir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.